Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event.

Patients are at increased risk for recurrent ischemic events after an acute coronary syndrome event.

Patients are at increased risk for recurrent ischemic events after an acute coronary syndrome event. Milvexian, an oral factor XIa inhibitor, may reduce the risk of major adverse clinical events with minimal bleeding risk. In this phase 3, randomized, placebo-controlled trial,…